<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B9878E68-1A1C-46A8-A97F-020C6B6FE09E"><gtr:id>B9878E68-1A1C-46A8-A97F-020C6B6FE09E</gtr:id><gtr:name>Oxford Biomedica (UK) Limited</gtr:name><gtr:address><gtr:line1>WINDRUSH COURT , TRANSPORT WAY</gtr:line1><gtr:city>OXFORD</gtr:city><gtr:postCode>OX4 6LT</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9878E68-1A1C-46A8-A97F-020C6B6FE09E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B9878E68-1A1C-46A8-A97F-020C6B6FE09E</gtr:id><gtr:name>Oxford Biomedica (UK) Limited</gtr:name><gtr:address><gtr:line1>WINDRUSH COURT , TRANSPORT WAY</gtr:line1><gtr:city>OXFORD</gtr:city><gtr:postCode>OX4 6LT</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>2213221.0</gtr:offerGrant><gtr:projectCost>3688701.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/28CB9FEB-2252-4CC7-A6F9-F168861F64B3"><gtr:id>28CB9FEB-2252-4CC7-A6F9-F168861F64B3</gtr:id><gtr:firstName>Katie</gtr:firstName><gtr:surname>Binley</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101872"><gtr:id>DF295360-0096-4707-9E00-2F6347105EDD</gtr:id><gtr:title>Clinical Development of OXB-102</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101872</gtr:grantReference><gtr:abstractText>Parkinson's disease is caused by the degeneration of nerve cells in part of the brain; leading to the loss of dopamine, a chemical messenger which plays a vital role in coordinating body movement. In early stages of PD, oral levadopa (L-DOPA) medication is effective in managing the symptoms that include tremor, muscle stiffness and slow physical movement. However, the body progressively loses its ability to convert L-DOPA to dopamine thereby reducing its effectiveness and leading to the development of uncontrolled motor function. Oxford BioMedica has developed a 'once-only' gene therapy approach to treat individuals with PD called OXB-102 that is administered once to the target region in the brain where it converts cells into a replacement dopamine factory. In essence, OXB-102 replaces a patient?s own lost source of the neurotransmitter analogous to the natural dopamine supply in the absence of PD.</gtr:abstractText><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2213221</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101872</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>